4.3 Article

Estimating the Contribution of Acute Gastroenteritis to the Overall Prevalence of Irritable Bowel Syndrome

期刊

出版社

KOREAN SOC NEUROGASTERONTEROL & MOTILITY
DOI: 10.5056/jnm.2012.18.2.200

关键词

Gastroenteritis; Irritable bowel syndrome; Prevalence

向作者/读者索取更多资源

Background/Aims Recent studies reveal that acute gastroenteritis can precipitate irritable bowel syndrome (IBS) symptoms leading to the concept of post-infectious IBS. However, the overall contribution of gastroenteritis to the total IBS prevalence is unknown. In this exercise we try to estimate the contribution of gastroenteritis in IBS using the published literature and a longitudinal approach. Methods Existing literature was reviewed to determine the incidence of IBS after gastroenteritis, the rate of remission over time, data on rates of gastroenteritis in a given population and any patterns of resistance to these effects in human populations. This produced 3 models. The first assumed all humans were susceptible to gastroenteritis and its ability to produce IBS. The second assumed (using meta-analysis data) that 90% of humans in a given outbreak would be resistant to this effect. The third model used a high gastroenteritis exposure rate as might be seen in military deployment. Results In model 1, the prevalence was unrealistically high with an eventual steady state of 43.6% of the population affected by IBS. In a very conservative approach (model 2), steady state was achieved after 10 years to an overall prevalence of 8.9%. Interestingly, based on a high 1 year exposure rate such as military deployment, the maximum prevalence (steady state) was reached before 1 year suggesting high risk. Conclusions Although hypothetical in approach, based on conservative estimates in existing literature the contribution of gastroenteritis to the overall prevalence of IBS is substantial.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Gastroenterology & Hepatology

Health Economic Studies Are Important for Patients With Irritable Bowel Syndrome and Their Gastroenterologists

Eric D. Shah, Sarah K. Ballou

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Review Gastroenterology & Hepatology

Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review

Elliot S. Coburn, Corey A. Siegel, Michael Winter, Eric D. Shah

Summary: HLH is rare among IBD patients treated with biologics, with most cases having identifiable infection or malignancy at diagnosis and a history of immunomodulator use. Survival rate is 70%, with risk factors possibly including younger age, male gender, Crohn's disease, and treatment induction phase.

DIGESTIVE DISEASES AND SCIENCES (2021)

Article Gastroenterology & Hepatology

Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis

Eric D. Shah, Lin Chang, Jessica K. Salwen-Deremer, Peter R. Gibson, Laurie Keefer, Jane G. Muir, Shanti Eswaran, William D. Chey

Summary: From the perspective of insurers, it is cost-effective to implement routine and algorithmic prescription drug coverage restrictions that require patients to first fail low-cost behavioral, dietary, and off-label treatments. These findings suggest the importance of addressing insurance coverage and drug pricing to provide optimal care for patients with IBS.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis

Eric D. Shah, Jessica K. Salwen-Deremer, Peter R. Gibson, Jane G. Muir, Shanti Eswaran, William D. Chey

Summary: This study assessed the cost-benefit of treatments for IBS with diarrhea from insurer and patient perspectives, finding that prescription drugs and neuro-modulators were preferred by patients due to reduced lost wages and out-of-pocket costs. Costs were critical determinants of treatment value, with divergent cost drivers explaining misalignment between patient and insurer preferences.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019

B. Joseph Elmunzer, Rebecca L. Spitzer, Lydia D. Foster, Ambreen A. Merchant, Eric F. Howard, Vaishali A. Patel, Mary K. West, Emad Qayed, Rosemary Nustas, Ali Zakaria, Marc S. Piper, Jason R. Taylor, Lujain Jaza, Nauzer Forbes, Millie Chau, Luis F. Lara, Georgios I. Papachristou, Michael L. Volk, Liam G. Hilson, Selena Zhou, Vladimir M. Kushnir, Alexandria M. Lenyo, Caroline G. McLeod, Sunil Amin, Gabriela N. Kuftinec, Dhiraj Yadav, Charlie Fox, Jennifer M. Kolb, Swati Pawa, Rishi Pawa, Andrew Canakis, Christopher Huang, Laith H. Jamil, Andrew M. Aneese, Benita K. Glamour, Zachary L. Smith, Katherine A. Hanley, Jordan Wood, Harsh K. Patel, Janak N. Shah, Emil Agarunov, Amrita Sethi, Evan L. Fogel, Gail McNulty, Abdul Haseeb, Judy A. Trieu, Rebekah E. Dixon, Jeong Yun Yang, Robin B. Mendelsohn, Delia Calo, Olga C. Aroniadis, Joseph F. LaComb, James M. Scheiman, Bryan G. Sauer, Duyen T. Dang, Cyrus R. Piraka, Eric D. Shah, Heiko Pohl, William M. Tierney, Stephanie Mitchell, Ashwinee Condon, Adrienne Lenhart, Kulwinder S. Dua, Vikram S. Kanagala, Ayesha Kamal, Vikesh K. Singh, Maria Ines Pinto-Sanchez, Joy M. Hutchinson, Richard S. Kwon, Sheryl J. Korsnes, Harminder Singh, Zahra Solati, Field F. Willingham, Patrick S. Yachimski, Darwin L. Conwell, Evan Mosier, Mohamed Azab, Anish Patel, James Buxbaum, Sachin Wani, Amitabh Chak, Amy E. Hosmer, Rajesh N. Keswani, Christopher J. DiMaio, Michael S. Bronze, Raman Muthusamy, Marcia I. Canto, V. Mihajlo Gjeorgjievski, Zaid Imam, Fadi Odish, Ahmed I. Edhi, Molly Orosey, Abhinav Tiwari, Soumil Patwardhan, Nicholas G. Brown, Anish A. Patel, Collins O. Ordiah, Ian P. Sloan, Lilian Cruz, Casey L. Koza, Uchechi Okafor, Thomas Hollander, Nancy Furey, Olga Reykhart, Natalia H. Zbib, John A. Damianos, James Esteban, Nick Hajidiacos, Melissa Saul, Melanie Mays, Gulsum Anderson, Kelley Wood, Laura Mathews, Galina Diakova, Molly Caisse, Lauren Wakefield, Haley Nitchie, Akbar K. Waljee, Weijing Tang, Yueyang Zhang, Ji Zhu, Amar R. Deshpande, Don C. Rockey, Teldon B. Alford, Valerie Durkalski

Summary: This study aimed to assess the prevalence and significance of digestive manifestations in patients with COVID-19. The research found that gastrointestinal symptoms were common in hospitalized COVID-19 patients, but were mostly mild and not independently associated with a more severe clinical course. Abnormal liver test results were also common, but not significantly linked to mechanical ventilation or death among these patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Editorial Material Gastroenterology & Hepatology

Breath Test or Duodenal Aspirate for Small Intestinal Bacterial Overgrowth: Still No Breath of Fresh Air

Eric D. Shah

DIGESTIVE DISEASES AND SCIENCES (2021)

Article Gastroenterology & Hepatology

ACG Clinical Guideline: Management of Irritable Bowel Syndrome

Brian E. Lacy, Mark Pimentel, Darren M. Brenner, William D. Chey, Laurie A. Keefer, Millie D. Long, Baha Moshiree

Summary: Irritable bowel syndrome (IBS) is a chronic disorder that significantly impacts patients' quality of life. The American College of Gastroenterology has developed a clinical guideline using GRADE methodology for the management of IBS, recommending a positive diagnostic approach, specific tests, treatments, and gut-directed psychotherapy to improve symptoms for patients with IBS.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Letter Gastroenterology & Hepatology

Psychological Health Among Gastroenterologists During the COVID-19 Pandemic: A National Survey

Eric D. Shah, Mohsen Pourmorteza, B. Joseph Elmunzer, Sarah K. Ballou, Georgios I. Papachristou, Luis F. Lara, Uche Okafor, Sheryl A. Pfeil, Darwin L. Conwell, Somashekar G. Krishna

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Article Rheumatology

Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts

Yossra Suliman, Suzanne Kafaja, Sunny J. Oh, Mohamed Alemam, Gianluca Bagnato, Giuseppina Abignano, Ram Raj Singh, Gillian Barlow, Xiaochen Liu, Isela Valera, Walter Morales, Ali Rezaie, Mark Pimentel, Francesco Del Galdo, Daniel E. Furst

Summary: The study shows that elevated anti-vinculin antibody levels are common in patients with SSc and suggests a potential link between increased anti-vinculin levels and gastrointestinal symptoms.

CLINICAL RHEUMATOLOGY (2021)

Article Gastroenterology & Hepatology

Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes

Stacy Weitsman, Shreya Celly, Gabriela Leite, Ruchi Mathur, Rashin Sedighi, Gillian M. Barlow, Walter Morales, Maritza Sanchez, Gonzalo Parodi, Maria Jesus Villanueva-Millan, Ali Rezaie, Mark Pimentel

Summary: This study compared the duodenal and stool microbiomes of PPI users and non-users, finding differences in the relative abundance of certain microbial families in the duodenal and stool microbiomes of PPI users. However, PPI use was not associated with higher rates of SIBO. The clinical implications of these findings remain unclear.

DIGESTIVE DISEASES AND SCIENCES (2022)

Editorial Material Gastroenterology & Hepatology

Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19

B. Joseph Elmunzer, Bethany J. Wolf, James M. Scheiman, William M. Tierney, Jason R. Taylor

GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System

Eric D. Shah, Darren M. Brenner, Vincent L. Chen

Summary: Chronic overlapping pain conditions and sex seem to influence the likelihood of discontinuation of two commonly prescribed secretagogues, while mood disorders, narcotics, and benzodiazepines may not. Routine assessment for comorbid COPCs prior to initiating therapy may optimize IBS-C treatment selection and outcomes.

DIGESTIVE DISEASES AND SCIENCES (2022)

Article Immunology

Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening

Mark S. Riddle, A. Louis Bourgeois, Allison Clifford, Suhi Jeon, Birgitte K. Giersing, Mark Jit, Marta Tufet Bayona, Jared Ovitt, William P. Hausdorff

Summary: Shigella, a gram-negative bacterium, is a major cause of severe diarrhea and dysentery in children under five in low- and middle-income countries. Despite the development of promising Shigella vaccine candidates, the recommendation and adoption of such vaccines may face challenges due to declining disease rates, complex immunization programs, and availability of other vaccines.

VACCINE (2023)

Editorial Material Public, Environmental & Occupational Health

Advances on the forefront of travellers' diarrhoea

Mark S. Riddle, Charles D. Ericsson, Robert Steffen

JOURNAL OF TRAVEL MEDICINE (2023)

Article Immunology

GMP manufacture of Shigellaflexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers

Christopher Duplessis, Kristen A. Clarkson, K. Ross Turbyfill, Ashley N. Alcala, Ramiro Gutierrez, Mark S. Riddle, Tida Lee, Kristopher Paolino, Hailey P. Weerts, Amanda Lynen, Edwin Oaks, Chad K. Porter, Robert Kaminski

Summary: Shigella species cause severe disease and an effective vaccine is urgently needed. InvaplexAR vaccine, a subunit vaccine approach, demonstrated increased immunogenicity in pre-clinical studies and was tested in a phase 1 trial, showing safety and potential for inducing immune responses.

VACCINE (2023)

暂无数据